• Overview
  • Eligibility
  • More info
  • Locations

Relative Bioavailability and Food Effect Study in Healthy Subjects Administered Two Different Formulations of LY3202626 (NCT03023826)

The purposes of this study are to determine: - If there are any differences in the way LY3202626 is handled by the body when taken in two different forms - Whether a high fat meal affects the way the body handles LY3202626 - How well tolerated LY3202626 is There are three (3) study periods for all participants. Participants will be admitted to the clinical research unit (CRU) each period and will be discharged from the CRU following the completion of 2 overnight stays and up to 36 hours after dosing with LY3202626. The study will last about 50 days, not including screening.
  • Drug: LY3202626 (R-Fasting)
    Administered orally
    • Drug: LY3202626 (T1-Fasting)
      Administered orally
      • Drug: LY3202626 (T1-Fed)
        Administered orally
        Ages eligible for Study
        21 Years and older
        Genders eligible for Study
        All
        Accepts Healthy Volunteers
        Accepts Healthy Volunteers
        Inclusion Criteria:
        • Are overtly healthy males or females, as determined by medical history and physical examination
        • Female participants must be of non-childbearing potential confirmed by medical history or menopause
        • Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m²) inclusive, at screening
        Exclusion Criteria:
        • Are investigative site personnel directly affiliated with this study and their immediate families
        • Are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
        • Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
        • Have previously completed or withdrawn from this study or any other study investigating LY3202626, and have previously received the investigational product
        • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
        • Have a history of head trauma with loss of consciousness within the last 5 years
        • Have known or ongoing psychiatric disorders

        1 locations

        Singapore (1)
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
          Not specified
          Singapore, Singapore, 117597
        Status:
        completed
        Type:
        Interventional
        Phase:
        Start:
        14 January, 2017
        Updated:
        18 June, 2017
        Participants:
        30
        A girl giving information about available additional trials.

        FindMeCure helps you find, understand and join clinical trials from all over the world.

        There are more clinical trials for your condition!